Home › Research › Mild cognitive impairment
The role of quantitative EEG biomarkers in Alzheimer’s disease and mild cognitive impairment: applications and insights
Yue Yuan, Yang Zhao. Frontiers in Aging Neuroscience, 2025-04-23
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alzheimer's disease (AD) is characterized by the pathological accumulation of amyloid plaques and hyperphosphorylated tau proteins, leading to disruptions in synaptic transmission and neural circuit alterations. Despite advancements in therapies to delay disease progression, there is a pressing need for simple, non-invasive, and accessible biomarkers to evaluate their effectiveness. Quantitative electroencephalography (qEEG), a computational method for quantifying brain electrical activity, is increasingly applied in AD research. We highlight the application of qEEG biomarkers, including power spectrum analysis (oscillatory activity within frequency bands), functional connectivity (coherent neural couplings) and effective connectivity (directional neural interactions), microstates (brief, stable states of the brain network), and non-linear analyses (e.g., entropy and EEG network analysis). These biomarkers can reflect real-time neural dynamics, making them ideal tools for diagnosis and monitoring the progression AD and mild cognitive impairment (MCI). It has been shown that decreased α power and increased θ power within the qEEG spectrum correlate with enhanced AD severity. Data from microstate analysis have demonstrated significant variations in temporal dynamics in patients with AD. Non-linear measures, such as entropy, have identified marked reductions in neural complexity in AD and MCI patients, indicating that they may serve as early diagnostic markers. Compared to traditional neuroimaging techniques, such as magnetic resonance imaging (MRI) or positron emission tomography (PET), qEEG is known to be cost-effective and facilitates real-time monitoring. Overall, qEEG biomarkers are promising for advancing AD research due to their non-invasive nature, affordability, and ability to capture real-time neural activity. Integrating qEEG with multimodal neuroimaging and clinical profiles may facilitate earlier identification and precision therapies. Future research should focus on standardizing protocols, validating biomarkers across diverse cohorts, and exploring their potential in large-scale clinical trials.
What this study adds
Evidence grade: Low
This review describes quantitative EEG biomarkers, including decreased alpha power and increased theta power correlating with Alzheimer's disease severity, as tools for diagnosis and monitoring. It presents no treatment, cure or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Yuan, Y., & Zhao, Y. (2025). The role of quantitative EEG biomarkers in Alzheimer’s disease and mild cognitive impairment: applications and insights. Frontiers in Aging Neuroscience. https://doi.org/10.3389/fnagi.2025.1522552
Vancouver
Yuan Y, Zhao Y. The role of quantitative EEG biomarkers in Alzheimer’s disease and mild cognitive impairment: applications and insights. Frontiers in Aging Neuroscience. 2025. doi:10.3389/fnagi.2025.1522552. PMID: 40336944.
BibTeX
@article{yuan2025-40336944,
author = {Yuan, Yue and Zhao, Yang},
title = {{The role of quantitative EEG biomarkers in Alzheimer’s disease and mild cognitive impairment: applications and insights}},
journal = {Frontiers in Aging Neuroscience},
year = {2025},
doi = {10.3389/fnagi.2025.1522552},
pmid = {40336944},
url = {https://doi.org/10.3389/fnagi.2025.1522552}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- It has been shown that decreased α power and increased θ power within the qEEG spectrum correlate with enhanced AD severity.
- Data from microstate analysis have demonstrated significant variations in temporal dynamics in patients with AD.
- Compared to traditional neuroimaging techniques, such as magnetic resonance imaging (MRI) or positron emission tomography (PET), qEEG is known to be cost-effective and facilitates real-time monitoring.
- Overall, qEEG biomarkers are promising for advancing AD research due to their non-invasive nature, affordability, and ability to capture real-time neural activity.
Why it matters
This review describes quantitative EEG biomarkers, including decreased alpha power and increased theta power correlating with Alzheimer's disease severity, as tools for diagnosis and monitoring. It presents no treatment, cure or prevention.
Study details
- Evidence strengthLow
How this study scored 45/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Frontiers in Aging Neuroscience) |
| Journal's citation record | 2 / 4 | Frontiers in Aging Neuroscience: journal h-index 174 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 49 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 16.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 5 / 6 | Cited 31.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 2 / 4 | Cited 49 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Yang Zhao: h-index 20 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | First Hospital of Jilin University: institution h-index 291 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40336944) |
| Free to read | 2 / 2 | Free to read |
| Total | 45 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.3389/fnagi.2025.1522552
- PubMed: 40336944
- Original source →
- Free full text: Frontiers in Aging Neuroscience →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Mild cognitive impairment from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.